Treatment of moderate to severe plaque psoriasis with concomitant efalizumab and narrow-band ultraviolet B phototherapy

Journal of Drugs in Dermatology

Volumn 7, Issue 10, 2008, Pages 947-952

  Kircik, Leon H ^a,b   Liu, Clive ^c,d   Goffe, Bernard S ^c,d  

^a INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^b Physicians' Skin Care LLC   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d Dermatology Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFALIZUMAB; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHOTOTHERAPY; PSORIASIS; SKIN; TREATMENT OUTCOME; ULTRAVIOLET RADIATION;

ADULT; ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOTOTHERAPY; PSORIASIS; SKIN; TREATMENT OUTCOME; ULTRAVIOLET RAYS;

EID: 59049097508     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Bos JD, De Rie MA. The pathogenesis of psoriasis: immunological facts and speculations. Immunol Today. 1999;20:40-46. (Pubitemid 29136549)
2. Dustin ML, Springer TA. Lymphocyte function-associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells. J Cell Biol. 1988;107:321-331.
3. Krueger J, Gottlieb A, Miller B, Dedrick R, Garovoy M, Walicke P. Anti-CD11a treatment for psoriasis concurrently increases circulating T-cells and decreases plaque T-cells, consistent with inhibition of cutaneous T-cell trafficking. J Invest Dermatol. 2000;115:333.
4. Teunissen MB, Sylva-Steenland RM, Bos JD. Effect of low-dose ultraviolet-B radiation on the function of human T lymphocytes in vitro. Clin Exp Immunol. 1993;94:208-213. (Pubitemid 23308390)
5. Fitzpatrick T, Ortonne JP. Fitzpatrick's Dermatology in General Medicine. 6th ed. New York: McGraw-Hill, 2003.
6. Gordon KB, Papp KA, Hamilton TK, et al. Efalizumab for patients with moderate to severe plaque psoriasis: A randomized controlled trial. JAMA. 2003;290:3073-3080. (Pubitemid 37548113)
7. Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med. 2003;349:2004-2013. (Pubitemid 37448923)
8. Menter A, Gordon K, Carey W, et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol. 2005;141:31-38. (Pubitemid 40144437)
9. Gottlieb AB, Hamilton T, Caro I, et al. Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial. J Am Acad Dermatol. 2006;54:S154-S163. (Pubitemid 43238298)
10. Yones SS, Palmer RA, Garibaldinos TT, Hawk JL. Randomized double-blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen-UV-A therapy vs narrowband UV-B therapy. Arch Dermatol. 2006;142:836-842. (Pubitemid 44079782)